Group Calls for Ban of Abbott’s ADD Drug
A 30-year-old Abbott Laboratories Inc. drug for attention deficit disorder poses an unacceptable risk of deadly liver damage and should be banned immediately, a U.S. consumer group said on Thursday.
Abbott sells the drug under the brand name Cylert, and generic companies sell a copycat version known as pemoline. Public Citizen said the drug had caused 21 cases of liver failure, including 13 that were fatal or required transplants.
Dr. John Grohol is the CEO and founder of Psych Central. He is an author, researcher and expert in mental health online, and has been writing about online behavior, mental health and psychology issues -- as well as the intersection of technology and human behavior -- since 1992. Dr. Grohol sits on the editorial board of the journal Cyberpsychology, Behavior and Social Networking and is a founding board member and treasurer of the Society for Participatory Medicine.Like this author?
Catch up on other posts by John M. Grohol, PsyD (or subscribe to their feed).
Comments
This post currently has no comments. You can read the comments or leave your own thoughts on our new comments page.
Trackbacks
Last reviewed: By John M. Grohol, Psy.D. on 25 Mar 2005
Published on PsychCentral.com. All rights reserved.
APA Reference
Grohol, J. (2005). Group Calls for Ban of Abbott’s ADD Drug. Psych Central. Retrieved on February 14, 2012, from http://psychcentral.com/blog/archives/2005/03/25/group-calls-for-ban-of-abbotts-add-drug/
Grohol, J. (2005). Group Calls for Ban of Abbott’s ADD Drug. Psych Central. Retrieved on February 14, 2012, from http://psychcentral.com/blog/archives/2005/03/25/group-calls-for-ban-of-abbotts-add-drug/
